ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) insider Sarina Tanimoto sold 100,000 shares of the company’s stock in a transaction on Tuesday, April 16th. The stock was sold at an average price of $9.28, for a total transaction of $928,000.00. Following the transaction, the insider now owns 1,647,447 shares of the company’s stock, valued at approximately $15,288,308.16. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Sarina Tanimoto also recently made the following trade(s):
- On Friday, March 22nd, Sarina Tanimoto sold 2,343 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $9.02, for a total transaction of $21,133.86.
- On Thursday, March 14th, Sarina Tanimoto sold 444 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $9.00, for a total transaction of $3,996.00.
- On Wednesday, February 28th, Sarina Tanimoto sold 98,778 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $9.02, for a total transaction of $890,977.56.
- On Monday, February 26th, Sarina Tanimoto sold 700 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $9.01, for a total transaction of $6,307.00.
ARS Pharmaceuticals Trading Down 6.8 %
Shares of NASDAQ SPRY opened at $8.44 on Friday. The stock has a market cap of $814.48 million, a price-to-earnings ratio of -14.81 and a beta of 0.83. ARS Pharmaceuticals, Inc. has a 52 week low of $2.55 and a 52 week high of $11.27. The company’s 50-day moving average price is $8.73 and its 200 day moving average price is $6.25.
Institutional Investors Weigh In On ARS Pharmaceuticals
Large investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC acquired a new stake in shares of ARS Pharmaceuticals during the 1st quarter worth about $2,627,000. Squarepoint Ops LLC acquired a new stake in shares of ARS Pharmaceuticals during the 1st quarter worth about $84,000. State Street Corp boosted its stake in shares of ARS Pharmaceuticals by 50.4% during the 1st quarter. State Street Corp now owns 129,191 shares of the company’s stock worth $841,000 after purchasing an additional 43,300 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of ARS Pharmaceuticals during the 1st quarter worth about $895,000. Finally, Ameriprise Financial Inc. acquired a new stake in shares of ARS Pharmaceuticals during the 1st quarter worth about $1,825,000. 68.16% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
SPRY has been the subject of a number of research analyst reports. SVB Leerink upgraded shares of ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating and increased their price target for the company from $6.00 to $18.00 in a report on Tuesday, March 5th. Leerink Partnrs upgraded shares of ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Tuesday, March 5th. William Blair upgraded shares of ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Tuesday, February 20th. Finally, Wedbush reiterated an “outperform” rating and issued a $19.00 price target on shares of ARS Pharmaceuticals in a report on Monday, March 11th.
View Our Latest Analysis on ARS Pharmaceuticals
About ARS Pharmaceuticals
ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.
Further Reading
- Five stocks we like better than ARS Pharmaceuticals
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Comprehensive PepsiCo Stock Analysis
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- How to Capture the Benefits of Dividend Increases
- 3 Steel Stocks Could Soar on New China Tariffs
Receive News & Ratings for ARS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.